3 results
Primary Objective: The primary objective of this study tTo determine the feasibility ofreduce the amount of surgical site infections using prophylactic NPWT in patients undergoing surgery to the foot and/or ankle. The NPWT device which we will use…
Objectives - Core StudyPrimary Objectives• To evaluate the effects of oral ALZ-801 in subjects with Early AD who have the APOE4/4 or APOE3/4 genotype, on the plasma biomarkers of core AD pathology and brain volumes* Primary Plasma Biomarker Outcome…
ALZ-801 is an oral agent that is being developed as a potential disease modifying treatment for AD. This 78-week Phase 3 study will focus on Early AD subjects who carry the APOE4/4 genotype, and is designed according to current regulatory guidance…